Literature DB >> 9448307

Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes.

L M Alvarez-Salas1, A E Cullinan, A Siwkowski, A Hampel, J A DiPaolo.   

Abstract

HPV-16 E6 and E7 genes are required to efficiently immortalize a broad spectrum of cell types including cervical keratinocytes. Therefore, the E6/E7 genes can be considered relevant targets for anti-cancer therapy. We produced several engineered hairpin (HP) ribozymes to specifically disrupt HPV-16 E6/E7 mRNA. After extensive biochemical characterization, one anti-E6 HP ribozyme (R434) was selected for in vivo testing because of its superior catalytic capabilities. When expressed in cis, R434 efficiently inhibited E6 in vitro translation. Cis-expression of the HP ribozyme with HPV-16 E6/E7 genes in normal human keratinocytes reduced the growth rate and prevented immortalization. RNA analysis by reverse transcription-PCR showed that E6/E7 transcripts were cleaved in post-transfected cells and virtually were eliminated after long term expression. Of interest, an inactive version of the HP also was able to significantly affect the immortalizing ability of E6/E7, probably through passive hybridization. The combination of passive and cleaving antisense RNA therefore is established as an effective inhibitor of HPV-16 E6/E7 immortalization.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9448307      PMCID: PMC18715          DOI: 10.1073/pnas.95.3.1189

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  63 in total

1.  A method for generating transcripts with defined 5' and 3' termini by autolytic processing.

Authors:  M Altschuler; R Tritz; A Hampel
Journal:  Gene       Date:  1992-12-01       Impact factor: 3.688

Review 2.  Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents.

Authors:  J J Rossi; N Sarver
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

3.  RNA catalytic properties of the minimum (-)sTRSV sequence.

Authors:  A Hampel; R Tritz
Journal:  Biochemistry       Date:  1989-06-13       Impact factor: 3.162

4.  A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1.

Authors:  O Yamada; G Kraus; L Luznik; M Yu; F Wong-Staal
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

Review 5.  Ribozymes in gene therapy.

Authors:  J D Thompson; D Macejak; L Couture; D T Stinchcomb
Journal:  Nat Med       Date:  1995-03       Impact factor: 53.440

6.  Inhibition of c-Ha-ras gene expression by hammerhead ribozymes containing a stable C(UUCG)G hairpin loop.

Authors:  M Koizumi; H Kamiya; E Ohtsuka
Journal:  Biol Pharm Bull       Date:  1993-09       Impact factor: 2.233

7.  Mutagenesis of the hairpin ribozyme.

Authors:  P Anderson; J Monforte; R Tritz; S Nesbitt; J Hearst; A Hampel
Journal:  Nucleic Acids Res       Date:  1994-03-25       Impact factor: 16.971

8.  Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18.

Authors:  Z Chen; P Kamath; S Zhang; L St John; K Adler-Storthz; E J Shillitoe
Journal:  Cancer Gene Ther       Date:  1996 Jan-Feb       Impact factor: 5.987

9.  Analysis of the biological role of human papilloma virus (HPV)-encoded transcripts in cervical carcinoma cells by antisense RNA.

Authors:  M von Knebel Doeberitz; L Gissmann
Journal:  Haematol Blood Transfus       Date:  1987

10.  The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A.

Authors:  W C Phelps; C L Yee; K Münger; P M Howley
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

View more
  22 in total

1.  Anti-HBV hairpin ribozyme-mediated cleavage of target RNA in vitro.

Authors:  Yu-Hu Song; Ju-Sheng Lin; Nan-Zhi Liu; Xin-Juan Kong; Na Xie; Nan-Xia Wang; You-Xin Jin; Kuo-Huan Liang
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

Review 2.  The hairpin ribozyme. Discovery, mechanism, and development for gene therapy.

Authors:  R Shippy; R Lockner; M Farnsworth; A Hampel
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

Review 3.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

Review 4.  Papillomavirus genome structure, expression, and post-transcriptional regulation.

Authors:  Zhi-Ming Zheng; Carl C Baker
Journal:  Front Biosci       Date:  2006-09-01

5.  A triplex ribozyme expression system based on a single hairpin ribozyme.

Authors:  Guillermo Aquino-Jarquin; María Luisa Benítez-Hess; Joseph A DiPaolo; Luis M Alvarez-Salas
Journal:  Oligonucleotides       Date:  2008-09

6.  Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein.

Authors:  K Butz; C Denk; A Ullmann; M Scheffner; F Hoppe-Seyler
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

7.  Regulation of the human papillomavirus oncoproteins by differential phosphorylation.

Authors:  P Massimi; D Pim; C Kühne; L Banks
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

Review 8.  Regulation of apoptosis by the papillomavirus E6 oncogene.

Authors:  Ting-Ting Li; Li-Na Zhao; Zhi-Guo Liu; Ying Han; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

9.  Head and neck cancer stem cells: the effect of HPV--an in vitro and mouse study.

Authors:  Alice L Tang; John H Owen; Samantha J Hauff; Jung Je Park; Silvana Papagerakis; Carol R Bradford; Thomas E Carey; Mark E Prince
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04-12       Impact factor: 3.497

10.  Human papillomavirus E7 induces rereplication in response to DNA damage.

Authors:  Xueli Fan; Yingwang Liu; Susan A Heilman; Jason J Chen
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.